Retos del Programa de Tamiz Metabólico de la Secretaría de Salud, México

Maldonado, Nazarea Herrera; Vázquez, Mónica Vergara; Trejo, Mirna Angélica Hinojosa; Flores, Erika Paola García

doi:10.18233/apm39no6pp1s-4s1716

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different screening approaches occur in the various hospitals, groups of hospitals, and government departments without any unified central coordination [ 1231 , 1234 , 1235 , 1236 ]. The Secretary of Health oversees the highest percentage coverage of Mexican newborns [ 1237 , 1238 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

Therrell,

Padilla,

Borrajo

et al. 2024

IJNS

View full text Add to dashboard Cite

Newborn bloodspot screening (NBS) began in the early 1960s based on the work of Dr. Robert “Bob” Guthrie in Buffalo, NY, USA. His development of a screening test for phenylketonuria on blood absorbed onto a special filter paper and transported to a remote testing laboratory began it all. Expansion of NBS to large numbers of asymptomatic congenital conditions flourishes in many settings while it has not yet been realized in others. The need for NBS as an efficient and effective public health prevention strategy that contributes to lowered morbidity and mortality wherever it is sustained is well known in the medical field but not necessarily by political policy makers. Acknowledging the value of national NBS reports published in 2007, the authors collaborated to create a worldwide NBS update in 2015. In a continuing attempt to review the progress of NBS globally, and to move towards a more harmonized and equitable screening system, we have updated our 2015 report with information available at the beginning of 2024. Reports on sub-Saharan Africa and the Caribbean, missing in 2015, have been included. Tables popular in the previous report have been updated with an eye towards harmonized comparisons. To emphasize areas needing attention globally, we have used regional tables containing similar listings of conditions screened, numbers of screening laboratories, and time at which specimen collection is recommended. Discussions are limited to bloodspot screening.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The Secretary of Health oversees the highest percentage coverage of Mexican newborns [1237,1238]. Interest in G6PD deficiency, and its addition to the official panel of tests in 2017, has resulted in several recent reports [1239][1240][1241].…”

mentioning

confidence: 99%

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

Therrell,

Padilla,

Borrajo

et al. 2024

IJNS

View full text Add to dashboard Cite

show abstract

“…If not treated timely, they may cause severe damage to the nervous system, interfere in the newborn's biological, psychological, and social adaptation, and cause disability or death. Thus, the importance of its early detection through NS and the performance of confirmatory tests to establish the diagnosis of these congenital metabolic diseases [1][2][3][4][5][6] . Newborn CDMs individually have a statistically reduced incidence.…”

Section: Introductionmentioning

confidence: 99%

Determination and comparison of neonatal screening biomarker cutoff points in Mexican newborns against the manufacturerÓ?s cutoff point

Cobos-Puc¹,

Martínez-Tapia²,

Martínez-Castillo³

et al. 2023

RMU

View full text Add to dashboard Cite

Objective:The objective of the study was to determine the cutoff points (CP) of nine neonatal screening biomarkers performed at the Laboratory of the Center for Neonatal and Genetic Studies in Mexico City, comparing them with the CP recommended by the manufacturer of the reagents. Materials and methods: A descriptive cross-sectional research was carried out. The study included 2805 newborns aged 1-30 days, who had a drop of dried whole blood collected on filter paper, then quantified for their concentrations of thyroid-stimulating hormone, thyroxine, phenylalanine, immunotrypsin, galactose-1-phosphate uridyltransferase, galactose, glucose-6-phosphate dehydrogenase, biotinidase, and 17-alpha hydroxyprogesterone, by immunofluorescence method (DELFIA, PerkinElmer LifeSciences time-resolved fluorometry). The cutoff point (excluding atypical values) was calculated with the data obtained for each test, and the mean and standard deviation were determined. Sensitivity and specificity were determined with receiver operating characteristic (ROC) curves. The determined CPs were compared with the CPs recommended by the manufacturer of the reagents. Results: Except for T4, it was shown that, when comparing the CP obtained, these were lower compared to the CPs recommended by the manufacturer. Conclusion: The CPs obtained in Mexican neonates differ from those recommended by the manufacturer. In addition, CPs are analytically acceptable, as they have high sensitivity and specificity. Consequently, these CPs can be used as a reference in clinical practice for the possible early detection of metabolic diseases in newborns.

show abstract

Retos del Programa de Tamiz Metabólico de la Secretaría de Salud, México

Cited by 2 publications

References 0 publications

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

Determination and comparison of neonatal screening biomarker cutoff points in Mexican newborns against the manufacturerÓ?s cutoff point

Contact Info

Product

Resources

About